Shopping Cart

The shopping cart is empty

View courses and libraries and add them to the cart

{{item.title}} {{item.ceu}} hour {{item.ceu}} hours {{item.price | currency}} {{ getItemDiscountedPrice(item.price, item.discountedAmount) | currency}} {{item.priceAdjusted | currency}}

{{item.title}} {{item.price | currency}} {{ getItemDiscountedPrice(item.price, item.discountedAmount) | currency}} {{item.priceAdjusted | currency}}

Customers who Purchased
this Activity also Purchased

PREMIUM

{{recommendationsA.Title}}

Article
{{recommendationsA.Ceu}} hour | {{recommendationsA.Price | currency}} Article
{{recommendationsA.Ceu}} hours | {{recommendationsA.Price | currency}} {{recommendationsA.Price | currency}}

{{recommendationsA.Type}} {{recommendationsA.Type}}

PREMIUM

{{recommendationsB.Title}}

Article
{{recommendationsB.Ceu}} hour | {{recommendationsB.Price | currency}} Article
{{recommendationsB.Ceu}} hours | {{recommendationsB.Price | currency}} {{recommendationsA.Price | currency}}

{{recommendationsB.Type}} {{recommendationsB.Type}}

Total

{{totalCEUs}} hour{{totalCEUs}} hours

{{cart.total_amount | currency}}

@media (max-width: 991px) { body { padding-top: 0; } .site-header { height: auto; min-height: 65px; } .site-header.fixed-top { position: relative; } .site-header .container-fluid { flex-flow: row wrap; } .nav-site-toggle { display: none; } .site-logo { position: static; top:auto; left:auto; transform: none; margin: 10px auto; order: 1; } .nav-site { width: 100%; position: static; overflow: visible; background-color: #ffffff; order: 3; } .nav-site-close { display: none; } .nav-site .nav-site-menu { width: 100%; height: auto; margin-left: 0; overflow: visible; } .nav-site .nav-item .dropdown-toggle::after{ display: none; } .nav-site .navbar-nav { margin: 0; padding: 0; position: relative; overflow: visible; overflow-y: visible; height: auto; } .nav-site .nav-breadcrumb { display: none; } .nav-site .nav-item .dropdown-toggle { background-color: #e1e1e1; text-transform: uppercase; } .nav-site .nav-item .dropdown-menu { position: static; margin: 0; } .nav-site .nav-site-menu .navbar-nav .nav-item.dropdown-resources { font-weight: bold; background-color: #F2F4F6; } .nav-user { order: 2; margin: 0 10px 10px 10px; width: 100%; text-align: center; } .nav-user .user-menu { flex-flow: row wrap; } .nav-user .user-menu .user-menu-toggle { } .nav-user .user-menu .dropdown-menu { display: block; width: 100% !important; position: static; float: none; } .nav-user .user-menu .dropdown-menu::before, .nav-user .user-menu .dropdown-menu::after { display: none; } } @media (min-width: 992px) { body { padding-top: 0; } .site-header { height: auto; min-height: 65px; margin-bottom: 500px; } .site-header.fixed-top { position: static; } .nav-site .nav-site-menu .navbar-nav .nav-item:hover > .dropdown-menu { display: block; position: absolute; } .nav-site .nav-site-menu .navbar-nav .nav-item:focus-within > .dropdown-menu { display: block; position: absolute; } .nav-site .nav-site-menu .navbar-nav .nav-item .dropdown-menu { display: block; position: absolute; } .nav-site .nav-site-menu .navbar-nav .nav-item .dropdown-menu.super { display: flex; flex-flow: row nowrap; position: absolute; } .nav-site .nav-site-menu .navbar-nav .nav-item .dropdown-menu.sm1 { left: -376%; padding-right: 20px; width: 548px; } .nav-site .nav-site-menu .navbar-nav .nav-item > .dropdown-menu.sm1:before { left: 80%; } .nav-site .nav-site-menu .navbar-nav .nav-item > .dropdown-menu.sm1:after { left: 80.2%; } .nav-site .nav-site-menu .navbar-nav .nav-item .dropdown-menu.sm2 { left: 44%; padding-right: 20px; min-width: 6rem; } .nav-site .nav-site-menu .navbar-nav .nav-item .dropdown-menu.sm2 .dropdown-item { min-width: 170px; } .nav-site .nav-site-menu .navbar-nav .nav-item > .dropdown-menu.sm2:before { left: 5%; } .nav-site .nav-site-menu .navbar-nav .nav-item > .dropdown-menu.sm2:after { left: 5.2%; } .nav-site .nav-site-menu .navbar-nav .nav-item.dropdown-resources { } .nav-user .user-menu .dropdown-menu { display: block; left: -20px; width: 210px !important; } .nav-user .user-menu .dropdown-menu .dropdown-item { min-width: 170px; } } .card-slider { overflow-x: auto; }

1. On which of the following SARS-CoV-2 variants is the newest updated COVID-19 mRNA monovalent vaccine based?

A. EB.5 B. EG.5 C. XBB.1.5 D. BA.2.86

2. In a recent study regarding antiviral therapy for long COVID in Medicare patients, what was the incidence range of long COVID experienced among these groups as well as those with no treatment?

A. 0%–5% B. 6%–10% C. 10%–15% D. 16%–20%

3. Which of the following best represents the benefits of duvelisib based on available data presented in this program?

A. Decreased hospitalizations B. Decreased 28-day mortality C. Increased 28-day mortality D. No benefit or worsening of outcomes

4. A study evaluating long COVID patients in Denmark demonstrated a lack of improvement of symptoms after 18 months in what percentage of participants?

A. 10%–19% B. 20%–29% C. 30%–39% D. >50%

5. With COVID-19 and influenza vaccines, what is the appropriate timing of coadministration?

A. At least 24 hours should elapse between administration of the vaccines. B. At least 7 days should elapse between administration of the vaccines. C. The vaccines may be administered simultaneously. D. Coadministration of the 2 vaccines is not currently recommended.

6. Which of the following is the most likely risk from simultaneous administration of RSV vaccines and COVID-19 vaccines?

A. Increased risk of Guillain-Barre syndrome B. Increased risk of Miller-Fisher syndrome C. Increased risk of local side effects D. Increased risk of long COVID symptoms

7. What were the primary findings within a Canadian study of participants with long COVID symptoms who subsequently received COVID-19 vaccines?

A. Appearance of new long COVID symptoms B. No change in long COVID symptoms C. Improvement in long COVID symptoms D. Worsening of long COVID symptoms

8. Which of the following populations would be most appropriate for the administration of Arexvy?

A. 32-year-old male with a past medical history of hypothyroidism B. 62-year-old female with no known comorbidities C. 26-year-old female with pregnancy at 33 weeks' gestation D. 55-year-old male who had a myocardial infarction at age 45

9. Which of the following was reported more often in the Abrysvo pregnant population within the clinical trial?

A. Guillain-Barre syndrome B. Low birth weight C. Confirmed severe RSV infection D. Twin births

10. Which of the following patients would most likely benefit from nirmatrelvir/ritonavir therapy from a cost-effective standpoint?

A. 32-year-old fully vaccinated male with no past medical history B. 46-year-old female with no comorbidities who is fully vaccinated and has had confirmed COVID-19 disease C. 53-year-old male with 2 episodes of COVID-19 who has no comorbidities D. 64-year-old female who has severe obesity and is unvaccinated

Evaluation Questions

11. To what extent did the program meet objective #1?

A. Excellent B. Very Good C. Good D. Fair E. Poor

12. To what extent did the program meet objective #2?

A. Excellent B. Very Good C. Good D. Fair E. Poor

13. Rate the effectiveness of how well the program related to your educational needs:

A. Excellent B. Very Good C. Good D. Fair E. Poor

14. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:

A. Excellent B. Very Good C. Good D. Fair E. Poor

15. Rate the quality of the faculty:

A. Excellent B. Very Good C. Good D. Fair E. Poor

16. Rate the effectiveness and the overall usefulness of the material presented:

A. Excellent B. Very Good C. Good D. Fair E. Poor

17. Rate the appropriateness of the examination for this activity:

A. Excellent B. Very Good C. Good D. Fair E. Poor

18. Rate the effectiveness of how well the activity related to your practice needs:

A. Excellent B. Very Good C. Good D. Fair E. Poor

19. Rate the effectiveness of how well the activity will help you improve patient care:

A. Excellent B. Very Good C. Good D. Fair E. Poor

20. Will the information presented cause you to change your practice?

A. Yes B. No

21. Are you committed to making these changes?

A. Yes B. No

22. As a result of this activity, did you learn something new?

A. Yes B. No

23. What is your practice setting or area of practice?

A. Community Pharmacy/Independent B. Community Pharmacy/Chain C. Hospital/Health Systems D. Administrative/Pharmacy Director E. Critical Care Pharmacy F. Long-term Care G. Managed Care/PBM H. Oncology I. Specialty Pharmacy J. Industry/Manufacturing

24. How many years have you been in practice?

A. <5 B. 5 – 10 C. 11 – 20 D. >20

« Return to Activity